Enzene Biosciences Ltd.
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Holding
- Established
- 2006-08-28
- Employees
- 251
- Market Cap
- -
- Website
- http://www.enzene.com
OPTIMAB® Biosimilar Demonstrates Non-Inferiority to Ranibizumab in nAMD Treatment
• A Phase III study demonstrates OPTIMAB®, a ranibizumab biosimilar, is non-inferior to innovator ranibizumab (Lucentis) in treating neovascular age-related macular degeneration (nAMD).
• The study found no significant difference in the proportion of patients losing fewer than 15 letters in BCVA between the OPTIMAB® and innovator ranibizumab groups after 12 weeks.
• Both OPTIMAB® and innovator ranibizumab significantly improved BCVA and reduced CSFT from baseline to week 12, with no significant differences between the groups.
• OPTIMAB® showed a comparable safety and immunogenicity profile to innovator ranibizumab, suggesting it could be a cost-effective alternative for nAMD treatment.
© Copyright 2025. All Rights Reserved by MedPath